No products in the cart.
Diagnostic hapten-carrier conjugates BSA-Gastrin 17 (G17), OVA-Gastrin 17 (G17), KLH-Gastrin 17 (G17) for Chronic atrophic gastritis (CAG)G17detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Cat:GMP-SMT-G17-Ag-Ab
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Gastrin-17 (G-17) is a protein that is specifically secreted from antral G cells, and it has been suggested that its serum level may reflect the severity of antral atrophy more accurately than serum total gastrin. However, other studies have demonstrated that the gastric serum profile is not reliable for use in the diagnosis of atrophy. A growing number of recent studies have reported on the utilization of G-17 as a diagnostic biomarker for Chronic atrophic gastritis (CAG).Genemedi produces core diagnostic ingredients for test of Chronic atrophic gastritis (CAG) and related syndrome.
GeneMedi offers Diagnostic hapten-carrier conjugates BSA-Gastrin 17 (G17), OVA-Gastrin 17 (G17), KLH-Gastrin 17 (G17) for Chronic atrophic gastritis (CAG) G17 detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Chronic atrophic gastritis (CAG) test are suitable for in functional ELISA, and other immunoassays in dignostics.
Product Description
|
Cat No.
|
GMP-SMT-G17-Ag-Ab
|
|
Product Name
|
BSA-Gastrin 17 (G17) / OVA-Gastrin 17 (G17)
|
|
Expression platform
|
Synthetic
|
|
Bioactivity validation
|
Gastrin 17 (G17) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in G17 level test of Gastric disease (Chronic atrophic gastritis (CAG)) and related syndrome evaluation
|
|
Products description
|
Competitive immunoassay-validated hapten-carrier conjugates BSA-Gastrin 17 (G17) / OVA-Gastrin 17 (G17) is Synthetic.
|
|
Purity
|
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
|
Cat No.
|
GMP-SMT-G17-Ag-Ab
|
|
Product Name
|
Anti-human Gastrin 17 (G17) mouse monoclonal antibody (mAb)
|
|
Expression platform
|
Hybridoma
|
|
Isotypes
|
Mouse IgG
|
|
Bioactivity validation
|
Gastrin 17 (G17) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Gastrin 17 (G17) antibodies in G17 level test of Gastric disease (Chronic atrophic gastritis (CAG)) and related syndrome evaluation.
|
|
Tag
|
mFc
|
|
Products description
|
Anti-human Gastrin 17 (G17) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
|
|
Specics
|
mouse
|
|
Purity
|
Purity: ≥95% （SDS-PAGE）
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
Previous slide
Next slide
Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)
Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
